Berkshire Asset Management lowered its position in Medtronic PLC (NYSE:MDT) by 0.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 74,286 shares of the medical technology company’s stock after selling 678 shares during the period. Berkshire Asset Management’s holdings in Medtronic PLC were worth $5,714,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. J. Goldman & Company purchased a new stake in shares of Medtronic PLC during the third quarter worth about $6,821,000. Crow Point Partners boosted its stake in shares of Medtronic PLC by 26.7% in the third quarter. Crow Point Partners now owns 545 shares of the medical technology company’s stock worth $36,000 after buying an additional 115 shares during the period. Eagle Asset Management boosted its stake in shares of Medtronic PLC by 83.5% in the third quarter. Eagle Asset Management now owns 82,204 shares of the medical technology company’s stock worth $5,502,000 after buying an additional 37,408 shares during the period. MUFG Americas boosted its stake in shares of Medtronic PLC by 7.6% in the third quarter. MUFG Americas now owns 144,758 shares of the medical technology company’s stock worth $9,691,000 after buying an additional 10,256 shares during the period. Finally, EQIS Capital Management boosted its stake in shares of Medtronic PLC by 651.1% in the fourth quarter. EQIS Capital Management now owns 15,292 shares of the medical technology company’s stock worth $1,176,000 after buying an additional 13,256 shares during the period.

Medtronic PLC (NYSE:MDT) opened at 75.92 on Monday. The company has a market cap of $106.76 billion and a price-to-earnings ratio of 43.38. The firm has a 50-day moving average of $76.36 and a 200-day moving average of $74.52. Medtronic PLC has a 52 week low of $55.54 and a 52 week high of $79.50.

Medtronic PLC (NYSE:MDT) last issued its earnings results on Thursday, December 3rd. The medical technology company reported $1.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.03. The business had revenue of $7.10 million for the quarter. The company’s quarterly revenue was up 61.7% on a year-over-year basis. During the same period last year, the firm posted $0.96 earnings per share. Equities analysts forecast that Medtronic PLC will post $4.38 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, January 15th. Shareholders of record on Thursday, December 24th were paid a dividend of $0.38 per share. This is a boost from Medtronic PLC’s previous quarterly dividend of $0.26. This represents a $1.52 annualized dividend and a yield of 2.00%. The ex-dividend date of this dividend was Tuesday, December 22nd.

A number of equities research analysts recently issued reports on MDT shares. RBC Capital reiterated an “outperform” rating on shares of Medtronic PLC in a research report on Tuesday, September 29th. Evercore ISI upgraded shares of Medtronic PLC from a “hold” rating to a “buy” rating and raised their price objective for the company from $70.94 to $80.00 in a research report on Thursday, October 8th. Deutsche Bank restated a “buy” rating on shares of Medtronic PLC in a research report on Thursday, October 15th. BTIG Research restated a “buy” rating and issued a $84.00 price objective on shares of Medtronic PLC in a research report on Wednesday, October 21st. Finally, Zacks Investment Research cut shares of Medtronic PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, November 10th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $86.13.

In other news, EVP Bryan C. Hanson sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the transaction, the executive vice president now owns 106,514 shares of the company’s stock, valued at $7,988,550. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Richard Kuntz sold 13,715 shares of the company’s stock in a transaction that occurred on Friday, December 4th. The shares were sold at an average price of $78.06, for a total value of $1,070,592.90. Following the completion of the transaction, the vice president now directly owns 108,086 shares of the company’s stock, valued at approximately $8,437,193.16. The disclosure for this sale can be found here.

Medtronic plc (NYSE:MDT) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.

12 Month Chart for NYSE:MDT

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.